Derazantinib and Atezolizumab in Patients With Urothelial Cancer

Inclusion Criteria: * Histologically-confirmed transitional cell carcinoma of the urothelium of the upper or lower urinary tract * Recurrent or progressing stage IV disease, or surgically unresectable, recurrent or progressing disease * Documented central FGFR genetic aberration (FGFR1, FGFR2, or FGFR3 mutations / short variants and rearrangements / fusions) (Note; Substudy 2 started with patients requiring an FGFR GA, but this requirement was removed from the protocol later on) * Measurable disease, as defined by the Investigator using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2 * Adequate organ functions as indicated by Screening visit local laboratory values Exclusion Criteria: * Receipt of prior cancer treatment within specific interval periods * Concurrent evidence of any clinically significant corneal or retinal disorder * History of clinically significant cardiac disorders * Known CNS metastases * Concurrent uncontrolled or active infection with human immunodeficiency virus * Active hepatitis B or chronic hepatitis B without current antiviral therapy * Active hepatitis C * Active tuberculosis * Severe bacterial, fungal, viral and/or parasitic infections on therapeutic oral or IV medication at the time of first dose of study drug administration